CSPC Pharmaceutical Group's (HKG:1093) Regorafenib tablets obtained drug registration approval from China's National Medical Products Administration as it passed the regulator's quality and efficacy consistency evaluation, a Monday bourse filing said.
The drug is indicated for the treatment of patients with metastatic colorectal cancer, gastrointestinal stromal tumor, and hepatocellular carcinoma.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.